BRIEF-Jounce Therapeutics Announces Results From Pre-Planned Data Review Of Innate Phase 2 Trial Of Jtx-8064 And Pimivalimab

Reuters2023-03-17

March 16 (Reuters) - Jounce Therapeutics Inc :

* JOUNCE THERAPEUTICS ANNOUNCES RESULTS FROM PRE-PLANNED DATA REVIEW OF INNATE PHASE 2 TRIAL OF JTX-8064 AND PIMIVALIMAB DEMONSTRATING DEEP AND DURABLE RESPONSES IN PLATINUM RESISTANT OVARIAN CANCER

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2320415392?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-03-17 05:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2320415392","market":"us","top_or_hot":-1,"title":"BRIEF-Jounce Therapeutics Announces Results From Pre-Planned Data Review Of Innate Phase 2 Trial Of Jtx-8064 And Pimivalimab","media":"Reuters","content":"<html><body><p>March 16 (Reuters) - Jounce Therapeutics Inc   :</p><p>   * JOUNCE THERAPEUTICS ANNOUNCES RESULTS FROM PRE-PLANNED DATA REVIEW OF INNATE PHASE 2 TRIAL OF JTX-8064 AND PIMIVALIMAB DEMONSTRATING DEEP AND DURABLE RESPONSES IN PLATINUM RESISTANT OVARIAN CANCER</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Jounce Therapeutics Announces Results From Pre-Planned Data Review Of Innate Phase 2 Trial Of Jtx-8064 And Pimivalimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Jounce Therapeutics Announces Results From Pre-Planned Data Review Of Innate Phase 2 Trial Of Jtx-8064 And Pimivalimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-03-17 05:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>March 16 (Reuters) - Jounce Therapeutics Inc   :   * JOUNCE THERAPEUTICS ANNOUNCES RESULTS FROM PRE-PLANNED DATA REVIEW OF INNATE PHASE 2 TRIAL OF JTX-8064 AND PIMIVALIMAB DEMONSTRATING DEEP AND ...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2320415392","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2320415392","pubTimestamp":1679003113,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"March 16 (Reuters) - Jounce Therapeutics Inc   :   * JOUNCE THERAPEUTICS ANNOUNCES RESULTS FROM PRE-","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","BK4196":"保健护理服务","BK4139":"生物科技","APR":"Apria, Inc.","SANA":"Sana Biotechnology, Inc.","BK4007":"制药","CGEM":"Cullinan Therapeutics"},"translate_title":"BRIEF-Jounce Therapeutics宣布Jtx-8064和Pimivalimab先天2期试验的预先计划数据审查结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNCE":0.9,"APR":0.8,"CGEM":0.8,"LABP":0.8,"LHDX":0.8,"SANA":0.8},"content_text":"March 16 (Reuters) - Jounce Therapeutics Inc   :   * JOUNCE THERAPEUTICS ANNOUNCES RESULTS FROM PRE-PLANNED DATA REVIEW OF INNATE PHASE 2 TRIAL OF JTX-8064 AND PIMIVALIMAB DEMONSTRATING DEEP AND DURABLE RESPONSES IN PLATINUM RESISTANT OVARIAN CANCERSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2320415392"}